FrancophonIA/ELRC3.0 huggingface dataset:
English: Patients should be monitored for renal toxicity and clofarabine should be discontinued as necessary.
Slovenian: Bolnike je treba spremljati glede toksičnosti za ledvice in, če je potrebno, prekiniti zdravljenje s klofarabinom.
English: • Complete disappearance of circulating blasts
Slovenian: • popolno izginotje blastov v krvnem obtoku
English: To date, the highest daily dose administered to human beings is 70 mg/m for 5 consecutive days (2 paediatric ALL patients).
Slovenian: Največji odmerek, ki so ga odmerili pri človeku, je 70 mg/m2 5 dni zaporedoma (2 pediatrična bolnika z ALL).
English: If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2
Slovenian: Če ni porabljeno takoj, je uporabnik odgovoren za čas in pogoje shranjevanja pred uporabo, ti pa ne bi smeli trajati dlje kot 24 ur pri 2 °C do 8 °C, razen če se je redčenje izvedlo v nadzorovanih in preverjeno aseptičnih okoliščinah.
English: Patients who have previously received a hematopoietic stem cell transplant (HSCT) may be at higher risk for hepatotoxicity suggestive of veno-occlusive disease (VOD) following treatment with clofarabine (40 mg/m2) when used in combination with etoposide (100 mg/m2) and cyclophosphamide
Slovenian: Bolniki s predhodno presaditvijo krvotvornih matičnih celic (hematopoietic stem cell transplant, HSCT) so lahko izpostavljeni povišanemu tveganju za hepatotoksično sugestivno venookluzivno bolezen (veno-occlusive disease, VOD) po zdravljenju s klofarabinom (40 mg/m2), kadar se le-ta uporablja skupaj z etopozidom (100 mg/m2) in ciklofosfamidom (440 mg/m2).
English: Accordingly, longer infusion times should be considered in children weighing  20 kg (see section 4.2).
Slovenian: Temu ustrezno je treba pri otrocih, ki tehtajo  20 kg, razmisliti o daljšem času infundiranja (glejte poglavje 4.2).
English: CRp = Complete Remission in the Absence of Total Platelet Recovery
Slovenian: PRt = Popolna remisija brez popolne obnovitve števila trombocitov
English: If a patient becomes pregnant during treatment with clofarabine, they should be informed of the possible hazard to the foetus.
Slovenian: Če bolnice med zdravljenjem s klofarabinom zanosijo, jih je treba obvestiti o morebitnih tveganjih za plod.
English: Dosing commenced at 11.25 with escalation to 15, 30, 40, 52 and 70 mg/m2/day by intravenous infusion for 5 days every
Slovenian: Odmerjanje se je začelo pri 11,25, odmerek pa so nato povečevali na 15, 30, 40, 52 in 70 mg/m2/dan z intravensko infuzijo 5 dni zaporedoma, vsakih 2 do 6 tednov, glede na toksične učinke in odziv.
English: Treatment cycles should be repeated every 2 to 6 weeks (from the starting day of the previous cycle) following recovery of normal haematopoiesis (i.e. ANC ≥ 0.75 × 10
Slovenian: Cikle zdravljenja je treba ponoviti vsakih 2 do 6 tednov (od začetnega dne prejšnjega cikla) po vzpostavitvi normalne hematopoeze (tj. ANC (Absolute Neutrophile Count - absolutno število nevtrofilcev) ≥ 0,75 × 109/l) in izhodiščnega delovanja organov.
English: Common: Hyperbilirubinaemia, jaundice, venoocclusive disease, increases in alanine (ALT)* and aspartate (AST)* aminotransferases, hepatic failure Uncommon: Hepatitis
Slovenian: Pogosti: hiperbilirubinemija, zlatenica, venookluzivna bolezen, povečanje vrednosti alanin- (ALT)* in aspartat(AST)* aminotransferaz, jetrna odpoved Občasni: hepatitis
English: Yearly, simultaneously with submission of Periodic Safety Update reports
Slovenian: Vsako leto, sočasno s predložitvijo Redno posodobljenih poročil o varnosti zdravila (PSUR).
English: • An M1 marrow that did not qualify for CR or CRp
Slovenian: • kostni mozeg M1, ki ni izpolnil pogojev za PR ali PRt
English: How to use Evoltra
Slovenian: Kako uporabljati zdravilo Evoltra
English: The pharmacokinetics of clofarabine were studied in 40 patients aged between 2 to 19 years old with relapsed or refractory ALL or AML.
Slovenian: Farmakokinetiko klofarabina so preučevali pri 40 bolnikih, starih od 2 do 19 let s ponovljeno ali neodzivno ALL ali AML.
English: Four renal adverse events in 115 patients were considered to be related to clofarabine, none of which were serious; haematuria (3 events) and acute renal failure (1 event) (see sections 4.3 and 4.4).
Slovenian: Za štiri neželene dogodke izmed 115 bolnikov so menili, da so povezani z uporabo klofarabina, med njimi nobeden ni bil resen: hematurija (3 dogodki) in akutna ledvična odpoved (1 dogodek) (glejte poglavji 4.3 in 4.4).
English: If persistent leukaemia is not evident, it is recommended that the dose for the next cycle be reduced by 25% of the previous dose following recovery of ANC to ≥ 0.75 × 10
Slovenian: Če ni znakov persistentne levkemije, se po vzpostavitvi vrednosti ANC ≥ 0,75 × 109/l priporoča zmanjšanje odmerka naslednjega cikla za 25 % prejšnjega odmerka.
English: Clofarabine AUC0-24 hours by baseline estimated creatinine clearance in patients aged between 2 to 19 years old with relapsed or refractory ALL or AML (n = 11 / n = 12) following administration of multiple doses of clofarabine by intravenous infusion (creatinine clearance estimated using Schwartz formula)
Slovenian: AUC0-24 ur klofarabina po ocenjenem izhodiščnem kreatininskem očistku pri bolnikih, starih 2 do 19 let s ponovljeno ali neodzivno ALL ali AML (n = 11/n = 12) po intravenskem infundiranju več odmerkov klofarabina (kreatininski očistek je bil ocenjen po Schwartzovi formuli)
English: The MAH shall provide yearly updates on any new information concerning efficacy and safety of the product in paediatric patients with acute lymphoblastic leukaemia who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response.
Slovenian: Imetnik dovoljenja za promet z zdravilom bo zagotovil letne posodobitve glede vseh novih informacij o učinkovitosti in varnosti zdravila pri pediatričnih bolnikih z akutno limfoblastno levkemijo, ki jim je bolezen recidivirala ali so odporni (potem ko so prejeli vsaj dve predhodni shemi) in pri katerih ni pričakovati, da bi katera koli druga terapevtska možnost prinesla trajen odziv.
English: Systemic inflammatory response syndrome (SIRS) or capillary leak syndrome SIRS, capillary leak syndrome (signs and symptoms of cytokine release, e.g., tachypnea, tachycardia, hypotension, pulmonary oedema) were reported as an adverse event in 5% (6/115) of paediatric patients (5 ALL, 1 AML) (see section 4.4).
Slovenian: O sindromu SIRS, sindromu kapilarnih razpok (znaki in simptomi izločanja citokinov, npr. tahipneja, tahikardija, hipotenzija, pljučni edem) kot o neželenem učinku so poročali pri 5 % (6/115) pediatričnih bolnikov (5 ALL, 1 AML) (glejte poglavje 4.4).
English: Excipients: Sodium chloride and water for injections.
Slovenian: Pomožne snovi: natrijev klorid in voda za injekcije.
English: If a patient experiences one or more severe toxicities (US National Cancer Institute (NCI) Common Toxicity Criteria (CTC) Grade 3 toxicities excluding nausea and vomiting), treatment should be delayed until the toxicities resolve to baseline parameters or to the point where they are no longer severe and the potential benefit of continued treatment with clofarabine outweighs the risk of such continuation.
Slovenian: Če se pri bolniku pojavi en ali več hudih toksičnih učinkov (3. stopnje po splošnih merilih toksičnosti (CTC - Common Toxicity Criteria) Narodnega inštituta za zdravljenje raka (NCI - National Cancer Institute) v ZDA, z izjemo navzee in bruhanja), je treba zdravljenje prestaviti, dokler se toksični učinki ne vrnejo na izhodiščne parametre ali do točke, ko niso več hudi in ko je morebitna korist nadaljevanja zdravljenja s klofarabinom večja od tveganja.
English: Individual duration remission and survival data for patients who achieved CR or CRp
Slovenian: Posamično trajanje remisije in podatki o preživetju za bolnike, ki so dosegli PR ali PRt najboljši odgovor čas do SR (tedni)
English: OUTER CARTON
Slovenian: ZUNANJA KARTONSKA ŠKATLA
English: The concomitant use of medicinal products that have been associated with hepatic toxicity should be avoided wherever possible (see sections 4.5 and 4.8).
Slovenian: Sočasni uporabi zdravil, ki so povezana s toksičnimi učinki na jetra, se je treba izogibati, kadarkoli je to mogoče (glejte poglavji 4.5 in 4.8).
English: Type I glass vial with bromobutyl rubber stopper, polypropylene flip-off cap and aluminium overseal.
Slovenian: Viala iz stekla tipa I z zamaškom iz bromobutilne gume, polipropilensko dvižno zaporko in aluminijastim tesnilom.
English: Adverse reactions considered to be related to clofarabine reported at frequencies ≥ 1/1,000 (i.e. in > 1/115 patients) in clinical trials and post-marketing
Slovenian: Neželeni učinki, za katere so v kliničnih preskušanjih in v obdobju trženja ocenili, da so povezani z uporabo klofarabina in so o njih poročali s pogostnostjo ≥ 1/1.000 (tj. pri > 1/115 bolnikov)
English: Sixty-four patients of 115 (55.7%) experienced at least one vascular disorders adverse event.
Slovenian: Pri štiriinšestdesetih bolnikih izmed 115 (55,7 %) je prišlo do vsaj enega neželenega dogodka v povezavi z žilnimi boleznimi.
English: The use of disposable gloves and protective garments is recommended when handling Evoltra.
Slovenian: Pri ravnanju z zdravilom Evoltra je priporočeno uporabljati rokavice za enkratno uporabo in zaščitna oblačila.
English: However, the pharmacokinetics of clofarabine in adults with relapsed or refractory AML following administration of a single dose of 40 mg/m clofarabine by intravenous infusion over 1 hour were comparable to those described above in patients aged between 2 to 19 years old with relapsed or refractory ALL or AML following administration of 52 mg/m clofarabine by intravenous infusion over 2 hours for 5 consecutive days.
Slovenian: Farmakokinetika pri odraslih bolnikih s ponovljeno ali neodzivno AML po intravenskem infundiranju enkratnega odmerka klofarabina 40 mg/m2 v 1 uri je bila primerljiva z zgoraj opisano farmakokinetiko pri bolnikih, starih od 2 do 19 let, s ponovljeno ali neodzivno ALL ali AML po intravenskem infundiranju 52 mg klofarabina/m2 v 2 urah 5 dni zaporedoma.
English: • Prophylactic administration of allopurinol should be considered if hyperuricemia (tumour lysis) is expected.
Slovenian: • Če sumite na hiperurikemijo (tumorsko lizo), je treba razmisliti o profilaktični uporabi alopurinola.
English: 9/l for more than 4 weeks from the start of the last cycle, it is recommended that the dose for the next cycle be reduced by 25%.
Slovenian: Če je vrednost ANC pri bolnikih več kot 4 tedne od začetka zadnjega cikla < 0,5 × 109/l, se priporoča zmanjšanje odmerka v naslednjem ciklu za 25 %.
English: Marketing Authorisation Holder Genzyme Europe B.V.
Slovenian: Imetnik dovoljenja za promet z zdravilom Genzyme Europe B.V.
English: Very common: Fatigue, pyrexia, mucosal inflammation Common: Multi-organ failure, systemic inflammatory response syndrome*, pain, chills, irritability, oedema, peripheral oedema, feeling hot, feeling abnormal
Slovenian: Zelo pogosti: utrujenost, pireksija, vnetje sluznice Pogosti: odpoved več organov, sindrom sistemskega vnetnega odziva*, bolečina, mrzlica, razdražljivost, edem, periferni edem, občutek vročine, nenormalno počutje
English: Patients with cardiac disease and those taking medicinal products known to affect blood pressure or cardiac function should be closely monitored during treatment with clofarabine (see sections 4.5 and 4.8).
Slovenian: Bolnike s srčnimi boleznimi in bolnike, ki jemljejo zdravila, za katere je znano, da vplivajo na krvni tlak ali delovanje srca, je treba med zdravljenjem s klofarabinom skrbno spremljati (glejte poglavji 4.5 in 4.8).
English: The safety profile of clofarabine has not been established in patients with severe renal impairment or patients receiving renal replacement therapy (see section 4.3).
Slovenian: Varnostni profil klofarabina pri bolnikih s hudo okvaro ledvic oz. pri bolnikih, ki prejemajo ledvično nadomestno terapijo, ni bil določen (glejte poglavje 4.3).
English: Dose reduction for patients experiencing non-haematological toxicities Infectious events
Slovenian: Zmanjšanje odmerka pri bolnikih, pri katerih se pojavijo nehematološki toksični učinki Dogodki, povezani z okužbami
English: Common: Maculo-papular rash, petechiae, erythema, pruritic rash, skin exfoliation, generalised rash, alopecia, skin hyperpigmentation, generalised erythema, erythematous rash, dry skin, hyperhidrosis Frequency not known: Stevens Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN)
Slovenian: Pogosti: makulo-papularni izpuščaj, petehije, eritem, srbeči izpuščaji, luščenje kože, generalizirani osip, alopecija, hiperpigmentacija kože, splošni eritem, eritematozni izpuščaji, suha koža, čezmerno znojenje Pogostnost neznana: Stevens-Johnsonov sindrom (SJS), toksična epidermalna nekroliza (TEN)
English: Tell your doctor or carer immediately if you experience any of the following as you may need to stop treatment: - if you get a fever or high temperature - because clofarabine reduces the number of blood cells made in the bone marrow, you may be more likely to catch infections; - if you have breathing difficulties, rapid breathing, or breathlessness; - if you feel a change in your heart rate; - if you suffer from dizziness (light-headedness) or fainting - it may be a symptom of low blood pressure; - if you feel sick or have diarrhoea (loose bowels); - if your urine is darker than usual - it is important to drink plenty of water to avoid dehydration; - if you get a rash with blisters or mouth ulcers; - if you lose your appetite, have nausea (feeling sick), vomiting, diarrhea, dark-colored urine and light-coloured stools, stomach pain, jaundice (yellowing of the skin and eyes), or if you feel generally unwell, these could be symptoms of an inflammation of the liver (hepatitis), or liver damage (hepatic failure); - if you pass little or no urine, or experience drowsiness, nausea, vomiting, breathlessness, loss of appetite and / or weakness (these may be signs of acute kidney failure / kidney failure).
Slovenian: Zdravnika ali skrbnika takoj obvestite, če imate naslednje težave, ker boste morda morali prekiniti zdravljenje: - če imate vročino ali zvišano telesno temperaturo - ker klofarabin zmanjša število krvnih celic, ki nastajajo v kostnem mozgu, zato obstaja večja verjetnost, da boste zboleli za okužbo; - če imate težave pri dihanju, dihate hitro ali ste zasopli; - če čutite spremembo hitrosti bitja srca; - če imate omotico (vrtoglavico) ali omedlevico - to so lahko znaki nizkega krvnega tlaka; - če vam je slabo ali imate drisko; - če je vaš urin temnejši kot ponavadi - pomembno je, da pijete veliko vode, da bi preprečili dehidracijo; - če se pojavi izpuščaj z mehurji ali razjede ustne sluznice; če izgubite apetit, občutite slabost v želodcu (siljenje na bruhanje), bruhate, imate drisko, temen urin in svetlo blato, bolečine v trebuhu, zlatenico (porumenelost kože in očesnih beločnic), ali če se na splošno slabo počutite, so to lahko simptomi vnetja jeter (hepatitisa) ali okvare jeter (odpovedi jeter).
English: Common: Haematuria* Common: Renal failure, acute renal failure
Slovenian: Pogosti: hematurija* Pogosti: odpoved ledvic, akutna odpoved ledvic
English: Each vial contains 180 mg of salt (sodium chloride).
Slovenian: Ena viala vsebuje 180 mg soli (natrijevega klorida).
English: The no-observable effect level for maternal toxicity in rats was 18 mg/m 2/day and in rabbits was more than
Slovenian: Odmerek, pri katerem niso opazili toksičnih učinkov na mater, je bil pri podganah 18 mg/m2/dan, pri kuncih pa več kot 12 mg/m2/dan.
English: Evoltra should not be handled by pregnant women.
Slovenian: Nosečnice ne smejo delati z zdravilom Evoltra.
English: There is no experience in patients with hepatic impairment (serum bilirubin > 1.5 x ULN plus AST and ALT > 5 x ULN) and the liver is a potential target organ for toxicity.
Slovenian: Ni izkušenj z uporabo pri bolnikih z okvaro jeter (serumski bilirubin > 1,5 x ULN plus AST in ALT > 5 x ULN) in jetra so potencialni tarčni organ za toksične učinke.
English: Suppression of bone marrow should be anticipated.
Slovenian: Pričakovati je treba supresijo kostnega mozga.
English: 37 Hollands Road
Slovenian: Paasheuvelweg 25
English: There is no experience in patients with hepatic impairment (serum bilirubin > 1.5 x ULN plus AST and ALT > 5 x ULN) and the liver is a potential target organ for toxicity (see sections 4.3 and 4.4).
Slovenian: Ni izkušenj z uporabo pri bolnikih z okvarjenim delovanjem jeter (serumski bilirubin > 1,5 x ULN plus AST in ALT > 5 x ULN) in jetra so potencialna tarča za toksične učinke (glejte poglavji 4.3 in 4.4).
English: Forty-one patients of 115 (35.7%) experienced at least one renal and urinary disorders adverse event.
Slovenian: Pri enainštiridesetih bolnikih izmed 115 (35,7 %) so poročali o vsaj enem neželenem dogodku bolezni ledvic ali sečil.
English: Excipient with known effect Each 20 ml vial contains 180 mg of sodium chloride.
Slovenian: Pomožne snovi z znanim učinkom Ena 20 ml viala vsebuje 180 mg natrijevega klorida.
English: Any patient who experiences a severe toxicity on a third occasion, a severe toxicity that does not recover within 14 days (see above for exclusions), or a life-threatening or disabling toxicity (US NCI CTC Grade 4 toxicity) should be withdrawn from treatment with clofarabine (see section 4.4).
Slovenian: Pri bolnikih, pri katerih se tudi tretjič pojavijo hudi toksični učinki, ki se ne izboljšajo v 14 dneh (glejte izjeme zgoraj), ali življenje ogrožujoči ali onesposabljajoči toksični učinki (4. stopnje po CTC NCI v ZDA), je treba zdravljenje s klofarabinom prekiniti (glejte poglavje 4.4).
English: Driving and using machines Do not drive or use any tools or machines if you feel dizzy, light-headed or faint.
Slovenian: Vpliv na sposobnost upravljanja vozil in strojev Če imate omotico, vrtoglavico ali omedlevico, ne vozite avtomobila in ne upravljajte z orodji ali stroji.
English: Intravenous infusion of 52 mg/m clofarabine produced equivalent exposure across a wide range of weights.
Slovenian: Pri intravenskem infundiranju 52 mg klofarabina/m2 je bila izpostavljenost pri bolnikih z zelo različno telesno maso enaka.
English: Evoltra contains the active substance clofarabine.
Slovenian: Zdravilo Evoltra vsebuje zdravilno učinkovino klofarabin.
English: Common: Anorexia, decreased appetite, dehydration Frequency not known: hyponatremia
Slovenian: Pogosti: anoreksija, zmanjšan apetit, dehidracija
English: Patients who underwent transplant while in continued remission*
Slovenian: PRt bolniki s presaditvijo med trajajočo remisijo* PRt
English: Pharmacokinetics in patients aged between 2 to 19 years old with relapsed or refractory ALL or AML following administration of multiple doses of clofarabine by intravenous infusion
Slovenian: Farmakokinetika pri bolnikih, starih od 2 do 19 let s ponovljeno ali neodzivno ALL ali AML po intravenskem infundiranju več odmerkov klofarabina
English: The diluted concentrate is chemically and physically stable for 3 days at 2
Slovenian: Razredčeni koncentrat je kemijsko in fizikalno stabilen 3 dni pri 2 °C do 8 °C ter pri sobni temperaturi (do 25°C).
English: Very common (may affect more than 1 in 10 people): anxiety, headache, fever, tiredness; feeling and being sick, diarrhoea (loose bowels); flushing, itching and inflamed skin, inflammation of mucus (moist) linings such as the mouth and other areas; you may have more infections than normal because Evoltra can lower the number of certain types of blood cells in your body; skin rashes which may be itchy, red, painful or peeling skin including palms of the hands and soles of the feet, or small reddish or purple spots underneath the skin.
Slovenian: Zelo pogosti (pojavijo se lahko pri več kot 1 od 10 oseb): tesnoba, glavobol, zvišana telesna temperatura, utrujenost; občutek slabosti in slabost, driska; oblivanje, srbeča in vneta koža, vnetje (vlažnega) roba sluznic, kot so usta in na drugih mestih; morda boste imeli več okužb kot navadno, ker zdravilo Evoltra lahko zmanjša število določenih vrst krvnih celic v telesu; kožni izpuščaji, ki so lahko srbeči, rdeči, boleči, ali luščenje kože na dlaneh in podplatih ali majhne rdečkaste ali vijolične pike pod kožo.
English: During the post-marketing period prolonged cytopaenias (thrombocytopaenia, anaemia, neutropaenia and leukopaenia) and bone marrow failure have been reported.
Slovenian: Med spremljanjem zdravila po dajanju le tega v promet so poročali o podaljšani citopeniji (trombocitopenija, anemija, nevtropenija in levkopenija) ter odpovedi kostnega mozga.
English: In the post-marketing period, following treatment with clofarabine, serious hepatotoxic adverse reactions of VOD in paediatric and adult patients have been associated with a fatal outcome.
Slovenian: Med spremljanjem zdravila po dajanju le tega v promet so pri pediatrični populaciji in pri odraslih po zdravljenju s klofarabinom poročali o hudih hepatotoksičnih dogodkih (VOD), povezanih s smrtnim izidom.
English: Each vial of Evoltra contains 180 mg of sodium chloride.
Slovenian: Ena viala zdravila Evoltra vsebuje 180 mg natrijevega klorida.
English: Evoltra 1 mg/ml concentrate for solution for infusion must be diluted prior to administration.
Slovenian: Zdravilo Evoltra 1 mg/ml koncentrat za raztopino za infundiranje je treba pred uporabo razredčiti.
English: *Each ml of concentrate contains 1 mg of clofarabine.
Slovenian: * Vsak ml koncentrata vsebuje 1 mg klofarabina.
English: Very common: Vomiting, nausea, diarrhoea Common: Mouth haemorrhage, gingival bleeding, haematemesis, abdominal pain, stomatitis, upper abdominal pain, proctalgia, mouth ulceration Frequency not known: Pancreatitis elevations in serum amylase and lipase, enterocolitis, neutropaenic colitis, caecitis
Slovenian: Zelo pogosti: bruhanje, navzea, diareja Pogosti: krvavitve v ustih, krvavitve iz dlesni, hematemeza, bolečina v trebuhu, stomatitis, bolečina v zgornjem delu trebuha, proktalgija, razjede v ustih Pogostnost neznana: pankreatitis, povečanje amilaze in lipaze v serumu, enterokolitis, nevtropenični kolitis, tiflitis
English: Therefore, a safe and effective dosage recommendation for patients < 1 year old has yet to be established.
Slovenian: Podatkov o farmakokinetiki, varnosti in učinkovitosti klofarabina pri dojenčkih ni. Varna in učinkovita priporočila za odmerjanje pri bolnikih starih < 1 leto je treba še ugotoviti.
English: breathlessness, cough; - vomiting blood, stomach ache, pain in the bottom; - bleeding inside the head, stomach, intestine or lungs, mouth or gums, mouth ulcers, inflamed mouth lining; - yellowing of the skin and eyes (also called jaundice), or other liver disorders; - bruising, hair loss, changes to skin colour, increased sweating, dry skin, or other skin problems; - pain in the chest wall or bones, neck or back pain, pain in limbs, muscles, or joints; - blood in urine; - failure of organs, pain, increased muscle tension, water retention and swelling in parts of the body, including the arms and legs, changes in mental state, feeling hot, cold or abnormal; - clofarabine may affect the levels of certain substances in the blood.
Slovenian: - podplutbe, izguba las, spremembe barve kože, čezmerno potenje, suha koža ali druge težave s kožo; - bolečina v steni prsnega koša ali kosteh, bolečina v vratu ali hrbtu, bolečina v okončinah, mišicah ali sklepih; - kri v urinu; - odpoved organov, bolečina, povečana napetost mišic, zadrževanje vode in otekanje v nekaterih delih telesa, vključno z rokami in nogami, spremembe duševnega stanja, občutek vročine, mraza ali nenormalno počutje; - klofarabin lahko vpliva na ravni nekaterih snovi v krvi.